Key result
Novel gene therapies and stent-based drug delivery show promise against in-stent restenosis.
Why the study?
In-stent restenosis is an increasingly frequent and histologically distinct pathobiologic process with limited pharmacologic and mechanical treatment options until recent advances.
Population
Patients with or at risk of coronary in-stent restenosis and animal models such as porcine
Comparison
Various mechanical treatments, radiation-based therapies, and novel preventive strategies including gene transfer
Design
Review of histology, pathogenesis, and treatment strategies
Authors
Loading...
Should not yet change ISR practice; leaves open clinical translation of local drug delivery and gene therapies.
This review highlights that while in-stent restenosis has been a growing challenge, emerging technologies like drug-eluting stents and gene therapies offer significant potential to reduce its incidence.
Lowe et al. (2002) conducted a review in Coronary in-stent restenosis. Treatments and prevention strategies for in-stent restenosis was evaluated. Recent advances in gene modification, gene transfer therapies, and local stent-based drug delivery systems offer promising new strategies for the prevention and treatment of in-stent restenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: